AML1-ETO Inhibits Maturation of Multiple Lymphohematopoietic Lineages and Induces Myeloblast Transformation in Synergy with ICSBP Deficiency by Schwieger, Maike et al.
 
J. Exp. Med. 
 

 
 The Rockefeller University Press • 0022-1007/2002/11/1227/14 $5.00
Volume 196, Number 9, November 4, 2002 1227–1240
http://www.jem.org/cgi/doi/10.1084/jem.20020824
 
1227
 
AML1-ETO Inhibits Maturation of Multiple 
Lymphohematopoietic Lineages and Induces Myeloblast 
Transformation in Synergy with ICSBP Deﬁciency
 
Maike Schwieger,
 
1 
 
Jürgen Löhler,
 
2 
 
Jutta Friel,
 
1 
 
Marina Scheller,
 
3
 
Ivan Horak,
 
3
 
 and Carol Stocking
 
1
 
1
 
Department of Cell and Virus Genetics, and the 
 
2
 
Molecular Pathology Group, Heinrich-Pette-Institut für 
Experimentelle Virologie und Immunologie, D-20251 Hamburg, Germany
 
3
 
Department of Molecular Genetics, Institute of Molecular Pharmacology, Freie Universität Berlin, D-12207
Berlin, Germany
 
Abstract
 
The translocation (8;21), generating the AML1-ETO fusion protein, is one of the most fre-
quent chromosomal abnormalities associated with acute myelogenous leukemia (AML). To
elucidate its role in oncogenesis, bone marrow (BM) cells were infected with a retroviral vector
carrying AML1-ETO and transplanted into mice. In contrast to previous transgenic mouse
models, we show that AML1-ETO directly stimulates granulopoiesis, suppresses erythropoiesis,
and impairs the maturation of myeloid, B, and T lymphoid cells in vivo. To determine the sig-
nificance of earlier findings that expression of the tumor suppressor ICSBP is often downregu-
lated in AML myeloblasts, AML1-ETO was introduced into BM cells derived from mice lack-
ing the interferon regulatory factor ICSBP. Our findings demonstrate that AML1-ETO
synergizes with an ICSBP deficiency to induce myeloblastic transformation in the BM, remi-
niscent of AML.
Key words: leukemia • translocation (genetics) • IFN regulatory factor • B cell differentiation • 
myeloid differentiation
 
Introduction
 
Acute myelogenous leukemia (AML)
 
*
 
 accounts for 
 
 
 
80%
of all adult acute leukemias. A distinct subset of these leu-
kemias, making up 
 
 
 
10% of all AML cases, is characterized
by a (8;21)(q22;q22) translocation and, morphologically, by
the presence of myeloblasts showing maturation in the
neutrophil lineage (1). The t(8;21) juxtaposes the 
 
RUNX1
 
gene on chromosome 21 with the 
 
CBFT1
 
 gene on chro-
mosome 8, generating the AML1-ETO fusion transcrip-
tion factor (2–4). This fusion protein consists of the NH
 
2
 
-
terminal portion of the AML1 protein fused in frame to the
nearly full-length ETO protein. The fact that the t(8;21) is
the sole cytogenetic abnormality in the majority of these
cases suggests that AML1-ETO plays a critical role both in
the distinctive phenotype and in the establishment of the
leukemia clone. However, the mechanism by which
AML1-ETO initiates or contributes to AML transforma-
tion is not clearly established.
AML1, the amino-terminal partner of the fusion protein,
is the DNA-binding subunit of the core-binding factor
(CBF) transcription factor complex. It forms heterodimeric
complexes with CBF
 
 
 
 and activates transcription from en-
hancer core motifs (TGT/cGGY), which are present in a
number of genes relevant to myeloid and lymphoid devel-
opment (for a review, see references 5–7). The Runt ho-
mology domain (RHD) (8) at the amino terminus of
AML1 is included in the fusion protein and has been
shown to be required for heterodimerization with CBF
 
 
 
and for DNA binding (9). In contrast, the transactivation
domain, mapped to the COOH terminus of AML1 and
shown to interact with the multifunctional transcriptional
coactivators p300 and CBP (10), is absent in the fusion
protein. In its place is the COOH-terminal partner, ETO,
which interacts with the nuclear receptor corepressor/
mSin3/histone deacetylase complex (11–14). The RHD of
AML1 thus targets the fusion protein, with its associated
repressor complex, to AML1 (CBF)-regulated genes, lead-
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entry site; PRE, posttranscriptional regulatory element; RHD, Runt ho-
mology domain. 
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ing to the repression of genes containing CBF-binding sites
in their promoter/enhancer region (12, 15, 16). Recent
work has shown that the RHD of AML1 also interacts di-
rectly with other transcription factors important in lym-
phoid and myeloid differentiation (17–22), presenting the
possibility that the ETO-corepressor complex of AML1-
ETO can be recruited to enhancer elements of a broad
spectrum of genes.
To establish an effective therapy regimen for t(8;21)
AML, it is important to establish an in vivo system in
which the critical events and target genes of AML1-ETO–
induced transformation can be identified and tested. Initial
attempts to mimic the t(8;21) in mice by a knock-in strat-
egy (23, 24) resulted in embryonic lethality, similar to that
observed in AML1 knock-out mice, which originally
demonstrated the importance of the CBF transcription
complex in the establishment of definitive hematopoiesis
(25–27). Although these mice confirmed that AML1-ETO
is a dominant inhibitor of normal AML1 function, they are
not useful models to study leukemia induction. To over-
come the embryonic mortality, several groups have estab-
lished conditional AML1-ETO transgenic mouse strains,
in which expression can be induced in myeloid progeni-
tors of adult animals (28–31). Although no overt pheno-
typic alterations were observed in vivo in these models,
AML1-ETO expression was shown to enhance the self-
renewal capacity of early multipotent cells in vitro and to
prime the cells for leukemic transformation (29–31), dem-
onstrating the importance of secondary genetic lesions for
AML1-ETO transformation.
As the hematopoietic stem cell (HSC) is the primary
transformed cell in AMLs (32–34), we sought to establish a
mouse model for t(8;21) AML by using retroviral vectors
which infect this compartment. For these experiments we
used FMEV retroviral vectors, which have been optimized
to yield high expression levels in the HSC (for a review,
see references 35 and 36). Importantly, coexpression of
eGFP enabled us to readily detect differences between
AML1-ETO transduced and nontransduced cells. Our
findings conclusively demonstrate that AML1-ETO di-
rectly impairs maturation of multiple lymphohematopoietic
lineages and stimulates granulopoiesis in vivo, but is not
sufficient to induce leukemia.
Several recent studies have implicated the IFN regula-
tory factor ICSBP (also known as IRF8) as a tumor sup-
pressor of myeloid neoplasias. The first support of this hy-
pothesis came from studies of mice deficient for ICSBP,
which developed a myeloproliferative disease, closely re-
sembling chronic myelogenous leukemia (CML) (37).
The ICSBP deficiency results in an expansion of the early
myeloid progenitor pool, probably due to an increased
sensitivity to proliferation stimuli and a decreased re-
sponse to apoptotic stimuli (38, 39). The relevance of this
observation in human leukemia was confirmed by the
demonstration that ICSBP is downregulated in 79 and
66% of patients with CML and AML, respectively (40,
41). A more recent study suggests that ICSBP may be a
target gene of deregulated tyrosine kinases that induce
 
myeloproliferation, as constitutive expression of ICSBP
inhibited the myeloid transformation capacity of BCR-
ABL, a chimeric tyrosine kinase generated by the 9;22
translocation that is a hallmark of CML (42). To deter-
mine if ICSBP deficiency cooperates with AML1-ETO–
induced impairment of differentiation to induce a acute
myeloid disorder, AML1-ETO was introduced into bone
marrow (BM) cells derived from ICSBP
 
 
 
/
 
 
 
 mice. Our re-
sults demonstrate that an ICSBP deficiency synergizes
with expression of AML1-ETO in the induction of my-
eloid tumorigenesis.
 
Materials and Methods
 
Retroviral Vectors and Generation of Infectious Pseudotyped Viral
Particles.
 
The full-length AML1-ETO cDNA was excised from
plasmid pUHD-AML1-ETO (provided by D. Tenen, Harvard
Institutes of Medicine, Boston, MA) by XbaI digestion, blunt-
ended, and inserted into the plasmid pSF91-I-eGFP-PRE
(R780) at the unique NotI site. SF91-EGFP-PRE is a FMEV
type vector (43) that differs from the previously described SF91
retroviral vector (44) by the insertion of an internal ribosome en-
try site (IRES)-eGFP cassette and the posttranscriptional regula-
tory element (PRE) of the woodchuck hepatitis virus (45). To
generate retroviral pseudotypes, retroviral vector plasmid DNA
was contransfected with a plasmid expressing the ecotropic 
 
env
 
(46) into Phoenix-GP packaging cells (provided by G. Nolan,
Stanford University, Palo Alto, CA), as described previously (47).
 
Retroviral Infection of BM Cells and Transplantations.
 
C57BL/6J-
Ly5.1-Pep3b mice were used as recipients for all BM transplan-
tations. C57BL/6J-Ly5.2 or ICSBP
 
 
 
/
 
 
 
-C57BL/6J-Ly5.2 mice
between 12 to 16 wk of age were used as a source of BM cells.
In this genetic background and when maintained as homozy-
gotes, ICSBP
 
 
 
/
 
 
 
 mice did not develop acute hematological dis-
orders in over a 2-y observation period. Mice had slightly in-
creased spleen weights (0.35 vs. 0.11 g) and increased number of
myeloid progenitors and precursors in BM and spleen, but nor-
mal blood counts. BM cells were harvested from tibiae and fe-
mura of male donor mice 4 d after intraperitoneal administration
of 5-fluorouracil (150 mg/kg; Lederle) and infected as described
previously (48). 12 h after the last infection, 10
 
6
 
 cells were trans-
planted by tail vein injection into lethally irradiated (9.5 Gy)
Ly5.2
 
 
 
 female recipients. To ensure normal erythropoiesis in
engrafted mice receiving ICSBP
 
 
 
/
 
 
 
 BM, the transplanted cells
were supplemented with one-tenth amounts of nontransduced
ICSBP
 
 
 
/
 
 
 
 BM cells. Serial transplantation was performed with
transduced ICSBP
 
 
 
/
 
 
 
 and ICSBP
 
 
 
/
 
 
 
 BM to ensure that the
vector-expressing cells were of HSC origin. All animal experi-
ments were approved by the Hamburg Office of Health (permit
no. 04/2000).
 
Western Blot Analysis.
 
Nuclear protein from Kasumi-1 cells
(49) or Phoenix cells transfected with the retroviral vector plas-
mid FMEV/AE or FMEV/GFP were prepared as described pre-
viously (50). 5 mg cell lysates were immunoprecipitated with the
polyclonal anti-ETO antibody (Oncogene Research Products)
and one-third of the precipitate was size-separated by 7.5% so-
dium dodecyl sulfate-polyacrylamide gel electrophoresis. West-
ern blot analysis were performed as described previously (50). A
1:200 dilution of the polyclonal anti-AML1 antibody (N-20,
Santa Cruz Biotechnology, Inc.) was used to detect protein ex-
pression. After incubation with the first antibody, the bound an-
tibody was detected with the appropriate secondary antibody 
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conjugated with HRP and visualized using the ECL (Amersham
Pharmacia Biotech).
 
Flow Cytometry.
 
For lineage marker analysis, single-cell sus-
pensions (10
 
6 
 
cells) were prepared from hematopoietic tissues af-
ter lysis of erythroid cells with PharmMLyse™ (BD PharMin-
gen) and incubated at 4
 
 
 
C for 30 min in PBS containing 2% BSA
with PE- or APC-conjugated mAbs (BD PharMingen). Nonspe-
cific binding of mAbs was prevented by preincubation with Fc
Block™ (BD PharMingen). Cells were washed twice with PBS
containing 2% BSA and applied for analysis on a FACScalibur™
(BD Biosciences) FACS
 
®
 
. A MoFlow™ Cell Sorter (Cytoma-
tion Bioinstruments) was used to sort transduced cells before col-
ony assays.
 
In Vitro Colony-forming Assays.
 
BM cells from either FMEV/
AE or FMEV/GFP mice were isolated from femura and tibiae
and sorted for GFP
 
pos
 
 expression. Single-cell suspensions (5 
 
 
 
 10
 
4
 
cells per milliliter and 10
 
5
 
 cells per milliliter) were plated in tripli-
cates in methylcellulose (MethCult™ GF M3434, StemCell
Technologies) and incubated at 37
 
 
 
C. Individual colonies were
scored 9 d after plating. Cytospins were made from representative
colonies and stained with Giemsa solution to confirm or deter-
mine cell morphology within a colony.
 
Histologic and Immunohistologic Methods.
 
Splenic and hepatic
tissue specimens were fixed with 4% formalin containing 1% ace-
tic acid. For histologic inspection of BM, sterna were dissected
and fixed in a formalin containing solution specifically developed
for fixation of iliac crest trephine biopsies (Protaqs Calfix,
Quaratett) and appropriately decalcified (Protaqs Calless, Quar-
atett) before paraffin embedding. Deparaffinated sections were
stained according to standard laboratory protocols with H&E, pe-
riodic acid Schiff solution, or a modified Wright-Giemsa stain (all
obtained from Sigma-Aldrich). For myeloperoxidase immuno-
staining of granulocytic cells an indirect immunoperoxidase stain-
ing technique was applied. In brief, for antigen retrieval, depar-
affinated sections were treated with a commercial “Target
Unmasking Fluid” (TUF, Dako) at 98
 
 
 
C for 20 min in a micro-
wave oven. Incubation with 1:15,000 diluted polyclonal rabbit
anti–human myeloperoxidase (Dako) antibody was done over-
night at 4
 
 
 
C. Specifically bound primary antibodies were de-
 
tected using a highly sensitive peroxidase- and polymer-conju-
gated anti–rabbit Ig detection system (Envision, Dako).
 
Results
 
Transduction and Transplantation of BM Cells with eGFP
and AML1-ETO–expressing Vectors.
 
The AML1-ETO cDNA
was introduced into a FMEV retroviral vector, which coex-
presses the eGFP behind an IRES (Fig. 1 A). Both virus ti-
ters and eGFP expression levels were reduced in infected
cells expressing the FMEV/AE construct as compared with
the control vector FMEV/GFP (Fig. 1 B), which may be
partly due to AML1-ETO transcriptional repression of the
vector via a pivotal CBF-binding site in the retroviral LTR
(51). Western blot analysis of protein extracted from FMEV/
AE-infected cells confirmed the presence of the AML1-
ETO protein with the same molecular weight as that found
in Kasumi-1 cells, a cell line established from a t(8;21) AML
patient (49) (Fig. 1 C). Exact quantification of AML1-ETO
protein levels produced by infected cells was precluded by
the immunoprecipitation step, but they appear to be some-
what lower as observed in Kasumi-1 cells.
BM cells were infected with comparable titers of
FMEV/AE or FMEV/GFP and then transplanted into le-
thally irradiated donors. At the time of transplantation, 10–
15% of the BM cells expressed the viral vector, as measured
by eGFP expression. After 3–6 mo, three animals of each
group (first cohort) were killed and the BM was used to
transplant five new mice each (second cohort).
 
Higher Proportion of AML1-ETO Transduced Cells in BM
as in Blood.
 
For both FMEV/AE and FMEV/GFP trans-
duced mice, a total of 14 and 9 mice, respectively, were
killed between 2 and 6 mo after BM transplantation. At
least 4–5 animals from each cohort were analyzed. Signifi-
cantly, no difference in leukocyte and differential counts in
the blood were observed between experimental and con-
Figure 1. Coexpression of
eGFP with AML1-ETO allows
detection of both transduced
and nontransduced cells. (A)
AML1-ETO cDNA was in-
serted into the FMEV/GFP vec-
tor, in which the translation of
eGFP is initiated from an IRES,
to generate FMEV/AE. Tran-
scription is initiated from the
SFFVp LTR. The PRE from
woodchuck hepaptitis virus in-
creases the expression levels. (B)
eGFP fluorescence was mea-
sured by flow cytometry in BM
cells obtained from mice trans-
planted with infected BM cells.
Reduced levels of expression
from FMEV/AE may be attrib-
utable, in part, to transcriptional
downregulation by binding of
AML1-ETO to the CBF-bind-
ing site in the LTR. (C) Western blot analysis of protein extracted from FMEV/AE- and FMEV/GFP-infected human cells was performed to confirm
AML1-ETO expression. Protein extracted from Kasumi-1 cells served as a control. 
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trol animals. The percentage of BM cells carrying the vec-
tor varied considerably between individual mice for both
FMEV/AE and FMEV/GFP (Table I), ranging from 6.1 to
73.6% and 3.8 to 51.5%, respectively. Although overall
higher levels of transduction were observed in BM receiv-
ing FMEV/AE, this was not statistically significant. Thus,
AML1-ETO expression neither imparts a selective advan-
tage nor disadvantage to repopulating cells.
However, a striking difference was observed when the
level of transduced cells in BM and blood was compared.
Whereas mice receiving FMEV/GFP–infected BM showed
similar or slightly higher levels of transduced (GFP
 
pos
 
) cells
in the blood as compared with the BM, the number of
transduced (AE
 
pos
 
) cells in the blood was reduced by a
mean factor of 2.7 relative to the BM in FMEV/AE mice
(Table I). This was observed in all mice analyzed, regard-
less of whether they received BM directly after retroviral
transduction (first cohort; 
 
n
 
 
 
 
 
 5) or BM from primary
 
transplants (second cohort; 
 
n
 
 
 
 
 
 9). In addition, no signif-
icant change in the ratio was observed in mice killed at
different time points (ranging from 69 to 218 d after
transplantation). This reduction in transduced cells in the
blood must thus be a direct consequence of AML1-ETO
expression.
The distribution of myeloid, as well as B and T lymphoid
cells in the transduced (AE
 
pos
 
; GFP
 
pos
 
) or nontransduced
(AE
 
neg
 
; GFP
 
neg
 
) populations in the blood was determined by
FACS
 
®
 
 analysis to ascertain if a particular lineage was un-
derrepresented in the AE
 
pos
 
 transduced blood cells (Fig. 2, A
and B). Greatly reduced numbers of transduced lymphoid
cells, in particularly those of the T cell lineage, was observed
in the AE
 
pos
 
 population. This distortion in lineage ratio
could not be attributed to a bias generated by retroviral
transduction, as the lineage ratio of GFP
 
pos
 
 transduced cells
was comparable to the nontransduced populations. Signifi-
cantly, in addition to a decrease in both B and T lymphoid
 
Table I.
 
Percentage of Transduced Cells in BM and Blood of Transplanted Mice
 
Percentage of GFP
 
pos
 
 cells
Ratio GFP
 
pos
 
(blood/BM) Transduced vector Mouse no.  Cohort Days
 
a
 
Blood  BM
FMEV-GFP 9 1 166 23.7 19.2 1.23
11 1 166 8.4 7.9 1.06
13 1 133 48.2 30.5 1.58
23 1 242 57.8 51.5 1.12
91 2 69 44.0 21.6 2.04
92 2 137 51.2 48.8 1.05
94 2 69 13.9 5.6 2.48
108 2 131 8.8 3.8 2.32
112 2 118 23.1 9.8 2.36
x 
 
  
 
1.69 
 
  
 
0.61
FMEV-AE 3 1 194 8.8 34.2 0.26
4 1 194 6.3 28.5 0.22
4.1 1 127 9.7 38.5 0.25
30 1 218 2.1 6.1 0.34
30.1 1 188 2.8 7.4 0.38
86 2 69 16.4 40.7 0.40
87 2 69 26.0 73.6 0.35
89 2 137 3.6 17.8 0.20
96 2 126 3.3 8.5 0.39
97 2 106 8.0 12.8 0.63
98 2 78 11.8 26.0 0.45
102 2 118 7.2 19.4 0.37
103 2 78 5.4 10.9 0.50
106 2 131 10.2 31.1 0.33
x  
 
  
 
0.36 
 
  
 
0.11
 
b
a
 
Number of days after transplantation.
 
b
 
P 
 
 
 
 0.001 as compared to GFP control mice. 
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cells (
 
 
 
13 and 3% of the expected number, respectively), a
48% decrease in the expected number of myeloid cells was
also observed in the AE
 
pos
 
 transduced population in the
blood. Again, no significant difference was observed be-
tween the lineage distribution in blood between the first co-
hort (
 
n
 
 
 
 
 
 4) and the second cohort (
 
n
 
 
 
 
 
 8). Notably, no
difference in spleen weights were observed between AE and
GFP mice and the spleen architecture appeared normal by
standard histological techniques. A reduction in the propor-
 
tion of AE
 
pos
 
 transduced cells located in the spleen as com-
pared with the BM was also observed, however due to great
variation between individual mice in both control and ex-
perimental cohorts, this was not quantified.
 
AML1-ETO Expression Perturbs Maturation of B Cell Lym-
phopoiesis in BM.
 
The observation that AE
 
pos
 
 transduced
cells are underrepresented in the blood as compared with
the BM suggested that either lineage differentiation was
blocked or that lineage-committed cells were unable to
egress the BM due to inefficient maturation. To address
this issue, the lineage distribution and the maturation status
of cells in the BM was determined by FACS
 
®
 
 analysis. As
the lymphoid lineage was greatly reduced in AE
 
pos
 
 popula-
tion in the blood, we first assessed their numbers and cell
surface markers. As depicted in Fig. 2 C, no significant dif-
ference in the proportion of B cells was observed in the
AE
 
pos
 
 fraction as compared with either the AE
 
neg
 
 fraction in
the same group of mice, or the GFP
 
pos
 
 fraction in control
mice. However, a striking difference in the expression level
of the B220 surface marker expression was observed in AE
 
pos
 
cells from mice of both the first and second cohorts. A rep-
resentative analysis is shown in Fig. 3 A. Whereas the un-
transduced AE
 
neg
 
 cell population showed relative equal lev-
els of a B220
 
med
 
 and B220
 
hi
 
 cells, the AE
 
pos
 
 cells were
almost exclusively B220
 
med
 
. Equal proportions of B220
 
hi
 
and B220
 
med
 
 were present in the GFP
 
pos
 
 transduced popu-
lation from control mice, ruling out a bias due to the retro-
virus per se (Fig. 3 A). This difference in expression levels
between AE
 
pos
 
 versus AE
 
neg
 
 lymphoid cells was also ob-
served with CD45, which is a product of the same gene
encoding B220, but due to alternative splicing does not
contain the B cell specific epitope present in B220. Nota-
bly, the levels of CD45 expression on other cell types was
not reduced (unpublished data).
B220
 
med
 
 expression is a characteristic of late pro-B, pre-B,
and immature B cells (52), thus cells were stained with an-
tibodies against IgM and CD43, two cell surface markers
that can resolve these differentiation stages. The majority
(74%; mean value of three mice) of the B220
 
pos
 
 AE
 
pos
 
 cell
fraction were IgM
 
hi
 
 CD43
 
neg
 
 B220
 
med
 
 and thus can be classi-
fied as immature B cells (Fraction E; reference 52); in con-
trast, these immature B cells made up only 10% (mean value
of four mice) of the B220
 
pos
 
 fraction of AE
 
neg
 
 or GFPpos
controls (Fig. 3 B). Indeed, the majority (65%) of cells in
the control transduced (GFPpos) or untransduced popula-
tions were mature B cells (B220hi CD43neg IgMmed-hi; Frac-
tion F), which made up only a small proportion of the
AEpos population.
In summary, B cell maturation of AEpos transduced cells
is impaired at the final stages of maturation. This impair-
ment appears not to be absolute, however, as an average of
47.1% of the B220 positive cells in the AEpos fraction in the
blood expressed high levels of B220 (n   6). Although this
is significantly lower than in the AEneg population of the
same mice (87%) or the GFPpos fraction of control mice
(90.7%; n   4), end maturation does occur. No obvious
correlation between AML1-ETO levels (as measured by
GFP levels) and maturation levels were discernible, but this
Figure 2. Number and lineage distribution of AEpos and GFPpos cells in
blood and BM. (A) Lineage distribution within the transduced (pos) and
nontransduced (neg) populations of blood from AE and GFP mice (n  
12 and n   7, respectively) was determined by measuring lineage-specific
marker expression against GFP expression. Expression of CD11b
(MAC-1), CD45R (B220), and a CD4/CD8 cocktail was used to deter-
mine the percentage of myeloid, B and T lymphoid cells, respectively,
within a given population. Shown are mean values with SDs. (B) The rel-
ative decrease in cell numbers in the AEpos blood population for each par-
ticular lineage as compared with the expected value is depicted. The ex-
pected value (set at 1.0 for each lineage) is based on the lineage
distribution of GFPpos cells in the blood. (C) Lineage distribution of trans-
duced and nontransduced cell populations in BM of GFP and AE mice (n  
7 and n   10, respectively) was determined as described above. Expres-
sion of TER119 was used to define cells of the erythroid lineage.1232 AML1-ETO Inhibits Maturation of Multiple Lymphohematopoietic Lineages
possibility cannot be entirely ruled out. Finally, histological
examination of BM did not reveal a significant increase in
apoptotic or necrotic cell death, thus we postulate that the
accumulation of AEpos immature B cells contribute to the
increased cellularity observed in the BM (see below).
AML1-ETO Mice Exhibit a Reduction in Erythropoiesis
Coupled with an Increase in Granulopoiesis Shifted to Immature
Cell Types. Although the proportion of lymphoid cells in
BM did not vary significantly between the different trans-
duced and nontransduced populations, a striking decrease
in the proportion of erythroid cells was seen in the AEpos
population (Fig. 2 C). In contrast to GFPpos or AEneg BM
cells, which contained a mean of 21.2% and 23.4% ery-
throid cells, respectively, this lineage made up only 7.3% of
the AEpos population (P   0.001 for both controls). A rela-
tive increase in granulopoiesis accompanied the erythro-
cytic hypoplasia in the AEpos transduced fraction in BM,
with an  10% increase over the mean proportion of my-
eloid cells in the nontransduced AEneg and control trans-
duced GFPpos populations (Fig. 2 C). Microscopial inspec-
tion of BM sections of mice containing  25% AEpos
transduced cells confirmed the medullary granulocytosis
and decrease in erythropoiesis (Fig. 4, A and B). Granulo-
cytic hypercellularity was observed in the BM in 4 out of 5
FMEV/AE transduced mice examined, which was con-
firmed by immunohistochemical demonstration of my-
eloperoxidase (unpublished data). Thus, both granulopoie-
sis and, to a lesser degree, lymphopoiesis is stimulated,
whereas erythropoiesis is significantly suppressed.
Closer examination of BM sections and cytospins from
FMEV/AE–infected mice also revealed a shift to immature
granulopoiesis, with an increased proportion of blast forms
(promyelocytes and myeloblasts) (Fig. 4, C and D). Differ-
ential counts of 500–1,000 nucleated cells revealed an av-
erage of 10.1% blasts (n   3), as compared with 3.1% (n  
3) blasts in GFP-infected controls. As only 20–41% AEpos
cells are present in the BM, the relative increase in blast
cells in the transduced cells must be higher. A reduction in
mature myeloid cells was confirmed by analysis of Gr-1
expression levels by flow cytometry, where the transduced
and nontransduced population could be examined inde-
pendently. The level of Gr-1 (Ly-6G) expression is directly
correlated with granulocyte differentiation and maturation
(53). As representatively shown in Fig. 5, Gr-1 expression
levels were consistently reduced by a mean factor of 6.8 on
AEpos cells as compared with AEneg cells in both the first
and second cohorts (n   2 and 3, respectively), as deter-
mined by mean fluorescence intensities after staining. In
contrast, no significant difference in Gr-1 expression levels
was observed between GFPpos and GFPneg cells (n   6) in
control animals.
AML1-ETO BM Cells Contain a High Percentage of In Vi-
tro Clonogenic Blasts. To assess the observed changes in
myeloerythroid differentiation, in vitro colony assays
were performed to determine if increased numbers of my-
eloid progenitors and/or decrease levels of erythroid pro-
genitors could be confirmed. BM cells from either
FMEV/AE or FMEV/GFP mice were sorted for GFPpos
expression and plated in methylcellulose under conditions
that detect both myeloid and erythroid progenitors. As a
second control, unsorted cells from FMEV/GFP were
also assayed. At day 9, a fourfold increase in total colony
numbers was observed in plates containing AEpos BM cells
as compared with control GFPpos cells sorted and assayed
in parallel (Table II). The majority of the AEpos colonies
(92%) displayed a unique but consistent morphology,
characterized by a tightly compacted center surrounded
by a few dispersed cells. Representative colonies were
picked and the cell morphology analyzed microscopically.
These colonies contained predominately myeloblasts and
promyelocyes ( 75%), with some macrophages and occa-
sional myelocytes and basophilic granulocytes (Fig. 4 E).
In  50 colonies of this morphology that were screened,
only rare metamyelocytes and segmented and banded
neutrophils were observed. Thus, the AEpos BM popula-
tion contains a large number of clonogenic myeloid pro-
Figure 3. B cells expressing AML1-ETO in the BM are impaired in
maturation at the immature B cell stage. (A) Flow cytometric analysis of
the cell surface marker CD45RA (B220) on BM cells from representative
mice receiving transplants of FMEV/AE- or FMEV/GFP-infected cells.
GFP expression was used to gate nontransduced (AEneg or GFPneg) or
transduced (AEpos or GFPpos) cells. The ratio of B220med to B220hi cells
(circled populations) for AEpos cells (7.9   3.7; n   7) was significantly
higher (P   0.001) than AEneg (1.1   0.9; n   7) and control GFPpos cells
(1.1   1.0; n   6). Furthermore, this increase was observed in the AEpos
fraction of animals from both the first and second cohorts (n   4 and 3, re-
spectively). (B) Histograms displaying the different B cell maturation stages
based on IgM and B220 expression levels. BM cells from transplanted
mice were gated for GFPpos/AEpos or GFPneg/AEneg expression. Fraction
D, E, and F, corresponding to preB cells, immature and mature B cells, re-
spectively, as defined by Hardy et al. (reference 52) are indicated.1233 Schwieger et al.
genitors that are impaired in differentiation. Colony assays
were only performed with BM cells from mice from the
second cohort (between 2.5 and 4.5 mo after transplanta-
tion) and not the first cohort, so we cannot exclude that
secondary transplantation has resulted in the selection of
this aberrant population.
Reduced levels of mature day 9 colonies were also ob-
served in AEpos as compared with GFPpos controls (Table
II), however, it is difficult to assess the significance of this,
as the large numbers of immature colonies may have inhib-
ited their growth. Variations in the distribution of these
mature colonies with regard to colony-forming type was
also seen, with a decrease in CFU-G (P   0.07) and a rela-
tive increase in CFU-M (P   0.01). No relative difference
in the proportion of BFU-E and CFU-GM colonies were
observed, suggesting that AML1-ETO either effects the
proliferation of these lineages at later stages of differentia-
tion or that both cell types are reduced at similar levels.
AML1-ETO Inhibits Myeloid and Lymphoid Differentiation
of ICSBP-deficient BM Cells and Imparts a Selective Repopulat-
ing Ability In Vivo. The results presented above demon-
strate that expression of AML1-ETO impairs myeloblast
differentiation. However, the BM environment is nonper-
missive for the growth and expansion of these differentia-
Figure 4. Morphological findings in mice transduced with AML1-ETO. (A) Sternal BM of a mouse with 41% AEpos cells from the second cohort
showing considerable hypercellularity associated with left shifted granulocytosis and reduced numbers of erythroid cells (note the compressed and ob-
scured sinusoidal vascular system). (B) In comparison, the marrow of an control animal is of normal cellularity with regular granulocytic and erythrocytic
compartments and a distended, well-defined sinusoidal vascular system. Higher magnification reveals increased numbers of blast-like and immature gran-
ulocytic cells in the BM of a the FMEV/AE transduced mouse (C) as compared with control mouse (D). (E) Typical myeloblast morphology of cells
picked from an immature colony and cytocentrifuged onto a glass slide. (A and B) H&E, magnification:  180. (C and D) Modified Giemsa stain, magni-
fication:  450. (E) Wright-Giemsa stain, original magnification:  500.1234 AML1-ETO Inhibits Maturation of Multiple Lymphohematopoietic Lineages
tion impaired cells. Thus, we sought to determine if the
deletion of the gene encoding ICSBP, which is often
downregulated in AML myeloblasts (41), would collabo-
rate with AML1-ETO expression to induce an acute my-
eloid disorder. BM cells of ICSBP /  mice were infected
with FMEV/AE and FMEV/GFP and used to transplant
lethally irradiated ICSBP /  mice. A second cohort of
mice was established after 90 d as described above.
Strikingly, the AEpos ICSBP /  population had a selec-
tive growth advantage in vivo over the nontransduced
cells, which was not observed in the GFPpos ICSBP / 
population. Although both groups of the first cohort re-
ceived 15% transduced cells, mice receiving FMEV/AE
transduced cells had an average of 36.7   22.2% trans-
duced cells after 5–7 mo (n   12), in contrast to an average
of 4.9   7.7% in mice receiving cells transduced with
FMEV/GFP (n   11; P   0.001 in a unpaired Student’s t
test). The rapid loss of GFPpos ICSBP /  BM cells, as com-
pared with the relative stable levels of GFPpos ICSBP / 
BM cells in the first and second cohorts, probably reflects a
competitive disadvantage of the ICSBP /  cells during re-
population as compared with ICSBP /  BM cells that
were added during the transplantation to ensure sufficient
levels of erythropoiesis in the regenerating BM, which is
deficient in ICSBP /  mice (37). Nevertheless, the AEpos
transduced ICSBP /  cells could compete with wild-type
cells for repopulation.
Mice receiving either FMEV/AE or FMEV/GFP
ICSBP /  BM with  6.5% transduction frequencies were
killed and screened for hematopoietic abnormalities in the
blood, spleen, and BM between 2 and 6 mo after transplan-
tation. Similar to the ICSBP /  mice, blood leukocyte lev-
els and differentiation counts were normal in both FMEV/
AE and FMEV/GFP ICSBP /  transduced mice. In addi-
tion, all FMEV/AE mice of both the first and second co-
horts (n   3 and 6, respectively) showed the same block in
lymphohematopoietic differentiation as described above for
ICSBP / -BM transplanted animals, as evidenced by the
number of transduced cells in the blood versus BM (0.33  
0.18 versus 1.45   0.47 for GFP controls), as well as an in-
crease in B220med over B220hi expression levels in BM cells
(5.3   2.2 for the AEpos population, in contrast to 1.1  
1.1 and 1.3   0.7 for AEneg and GFPpos populations, re-
spectively) and a 5.4 reduction in the mean fluorescence of
Gr-1 levels in the AEpos versus AEneg BM populations.
ICSBP Deficiency Synergizes with AML1-ETO to Trans-
form Myeloblasts in the BM and to Induce Granulocytic Sarcoma-
like Neoplasias. In striking contrast to the ICSBP /  BM
recipients, mice receiving ICSBP /  BM showed markedly
increased granulopoiesis with enhanced blast cell formation
in the BM, as revealed by histological and immunohis-
tochemical staining and confirmed by FACS® analysis (Fig.
6, A and B, and unpublished data). Differential counts of
cytospins of FMEV/AE transduced BM cells revealed an
average of 25.3   5.4% blasts (n   4), as compared with
5    1.2% (n    3) in control FMEV/GFP transduced
ICSBP /  BM mice. In addition to their increased num-
bers, blasts displayed an abnormal morphology (e.g., en-
hanced basophilic cytoplasm and enlarged nuclei with
pathological chromatin structures) (Fig. 6 C). In further
support of a neoplastic transformation, immature myeloid
cells were observed invading periosseous tissue of the bone
(e.g., sternum and femur) via the nutrient foramen to form
granulocytic sarcoma-like tumors in one out of three mice
Table II. Clonogenic Progenitor Assay Reveals a Differentiation Block in Myeloid Progenitors
BMa No. of colonies per 105 cellsb Mean distribution of mature colonies (%)
Immature Mature CFU-Mix CFU-GM CFU-G CFU-M BFU-E
AEpos 196   60 17   7 6.1 19.3 7.2 42.0 24.2
GFPpos 0 49   22 2.3 14.9 20.15 29.4 33.8
Unsortedc 0 50   28 8.2 15.2 17.7 29.4 31.2
aBM was isolated from femurs and tibiae and then either sorted for eGFP expression or assayed directly. 
bThe mean value and SD from three independent mice for each group performed in triplicate at two different cell concentrations are presented.
cUnsorted cells from FMEV-GFP–infected transplants.
Figure 5. A shift to more immature forms in the granulocytic compart-
ment is confirmed by expression levels of the GR-1 antigen. Representa-
tive FACS® profile of BM cells from transplanted mice as described in
Fig. 3. The mean fluorescence of GR-1 expression was reduced by a
mean factor of 6.8   4.4 in AEpos cells (n   5) as compared with the non-
transduced AEneg cells, in contrast to the GR-1 mean fluorescence of
GFPpos and GFPneg, which did not vary (ratio of 1.1   0.1; n   6).1235 Schwieger et al.
from the first cohort and three out of five mice from the
second cohort (Fig. 6 D). Significantly, granulocytic sarco-
mas are observed at a relatively high incidence in t(8;21)
AML (54, 55), and can be the first manifestation of AML
(56, 57). Similar lesions were not observed in control mice
receiving FMEV/GFP infected ICSBP /  BM, in mice re-
ceiving FMEV/AE ICSBP /  BM, nor in nontransplanted
ICSBP /  mice maintained in parallel in our facilities. De-
spite the unrestricted local proliferation of BM cells ob-
served in these AE ICSBP /  mice, the spleen, liver, and
blood remained devoid of infiltrating blasts. Their absence
in the spleen was striking, as lymphohematopoietic neopla-
sias often arise simultaneously in the splenic red pulp and
BM of mice (unpublished data). One explanation is offered
by the observation that BM provides the more favored mi-
croenvironment for granulopoiesis after transplantation and
thus may offer the necessary milieu for the transformation
potential of AML1-ETO.
Approximately 12 mo after transplantation, three mice
from each of the first cohorts receiving FMEV/AE-infected
ICSBP /  or ICSBP /  BM were killed and analyzed. Mice
receiving AE-transduced wild-type BM showed the same
phenotype as mice analyzed six months earlier, with no
signs of disease progression. In contrast, in one of the three
mice receiving AE-transduced ICSBP / , transformed my-
eloid blast cells were no longer restricted to the bone, but
had infiltrated the liver, kidneys, and spleen in large num-
bers, forming granulocytic sarcomas exhibiting myeloper-
oxidase immunopositivity (unpublished data). The rela-
tively long latency and clonality of this tumor, as assessed
by the retroviral integration site, supports the hypothesis
that additional mutation(s) is/are required for the trans-
formed myeloblasts, generated by the synergistic action of
AML1-ETO expression and ICSBP deficiency, to progress
to a full-blown AML.
Discussion
Several groups have attempted to demonstrate the onco-
genic potential of AML1-ETO expression in inducible
transgenic mouse models, but no overt alterations in vivo
have been observed or reported previously (28–31). In
contrast, by introducing AML1-ETO by retroviral trans-
duction into murine adult HSC, the origin of t(8;21) (33)
and the target cell of AML transformation (32, 34), we
could demonstrate that normal hematopoiesis is disrupted
at several levels by AML1-ETO expression in vivo. Similar
results were also recently reported by de Guzman et al. us-
Figure 6. Morphological findings in ICSBP /  mice transduced with AML1-ETO. (A and B) The sternal BM of an AML-ETO1 transduced
ICSBP /  mouse with 40% AEpos cells (A) is characterized by left-shifted granulocytosis with many blasts and immature granulocytic cells and the ab-
sence of erythrocytes, while a nontransduced ICSBP /  control animal (B) reveals a moderate and mature granulocytosis, and a moderately decreased
erythrocytosis which is constitutive for the ICSBP null mutation. (C) Greatly increased numbers of myeloblast, promyelocytes, and myelocytes are
present in a cytocentrifuged cell preparation of BM cells from an AML1-ETO transduced ICSBP /  mouse with 55% AEpos cells as compared with the
more mature granulocytic differentiation of nontransduced ICSBP /  marrow cells. (D) Predominately immature granulocytic BM cells invading via a
nutrient foramen of the sternum (arrow) into the periosseous connective tissue (bottom section of the microphotograph). (A and B) Modified Giemsa
stain, magnification:  450. (C) Wright-Giemsa stain, magnification:  500. (D) Modified Giemsa stain, magnification:  210.1236 AML1-ETO Inhibits Maturation of Multiple Lymphohematopoietic Lineages
ing a retroviral approach (58). Although it is not entirely
clear why transgenic animals models failed to manifest these
hematopoietic lesions, several factors must be considered.
Clearly, in addition to expression levels, both the temporal
and spatial patterns of expression are sure to be decisive fac-
tors in the ensuing phenotype. In our system, expression
levels are relatively constant in all hematopoietic cell com-
partments, including the HSC (35), thus ensuring that ex-
pression is achieved in the appropriate target cells. Another
contributing factor to the success of a retroviral approach,
may be due to the perturbation of the HSC pool during
the BM cell transplantation. The activation of this com-
partment may trigger the necessary cellular milieu for the
transforming action of AML1-ETO. Although Higuichi et
al. also transplanted BM from their knock-in mice into
syngeneic recipients (31), subtle changes in BM cells ex-
pressing AML1-ETO may have gone undetected due to
their inability to track these cells with a marker such as
GFP. Finally, the potential importance of slight variations
in the genetic background in these different mouse models
cannot be ignored.
The most striking observation in our mouse model of
AML1-ETO was the inhibition of maturation of both lym-
phoid and myeloid cells. This was initially most evident in
the lymphoid lineage, where the majority ( 85%) of
AML1-ETO cells remained at immature stages of differen-
tiation, as revealed by strikingly low levels in the blood.
We could demonstrate that the impaired B cell maturation
in cells expressing AML1-ETO occurred at a late stage, as
evidenced by the accumulation of B220med IgMhi pheno-
type in the AML1-ETO–expressing BM. Maturation was
not completely blocked, however, as mature B220hi B cells
in the AEpos fraction were found in the blood, albeit at low
levels. Preliminary results also suggest that the T cell devel-
opment is also blocked at a late stage of maturation, as dou-
ble positive (DP) CD4 /CD8  thymocytes are present at
normal levels in the AML1-ETO transduced population as
compared with controls in the thymus (unpublished data),
but very few AML1-ETO T cells are found in the blood.
This hypothesis is supported by recent studies that have
demonstrated the importance of the AML1/CBF  com-
plex in the transition and maturation of DP CD4 /CD8 
to single positive thymocytes (59, 60). Significantly, the
knock-in transgenic model of Higuichi et al., also reported
the unexpected absence of AML1-ETO transcripts in ma-
ture T cells (31). More important, although AML1-ETO
transcripts are detectable in HSC with lymphohematopoi-
etic potential in AML patients, they were not found in ma-
ture T cells and only detectable in B cells at a frequency
one-tenth of that observed in monocytes (33). We postu-
late that mature B and T cells preferentially arise from
HSCs not carrying t(8;21), due to the impaired maturation
of these lineages in cells expressing AML1-ETO.
In addition to the maturation block in lymphopoiesis, a
pronounced increase in granulopoiesis accompanied by a
decrease in erythropoiesis was another consistent pheno-
type observed in AML1-ETO transduced BM. The latter
phenotype must be a direct consequence of AML1-ETO
expression and not a displacement effect due to granulocy-
tosis, as a 70% reduction in erythroid cell proportions was
specifically observed in AEpos cells and not in AEneg non-
transduced cells. In addition to increased levels of granu-
lopoiesis, a distinct left shift, characterized by the accumu-
lation of more immature forms including blasts, was
documented both by FACS® and immunohistochemical
analysis. The differentiation defect in the myeloid lineage
was most strikingly demonstrated in in vitro colony assays,
where up to 92% of the clonogenic colonies contained pri-
marily myeloblast or promyelocytic cells. Notably, and
consistent with the t(8;21) AML phenotype (1), granulo-
cytic differentiation was impaired but not completely
blocked in our mouse model, as evidenced by the develop-
ment of normal granulocytic colonies in vitro from AEpos-
sorted cells, as well as GR-1hi–expressing cells in the blood
and spleen in the AEpos fraction. Although it has been pre-
viously postulated that AML1-ETO exerts its effect by
blocking granulocytic differentiation (18, 61–64), the use
of leukemic cell lines, which have multiple mutations and
limited differentiation potential, limited the interpretation
of these earlier results. Interestingly, a left shift in granu-
lopoiesis was not previously observed in transgenic AML1-
ETO mouse models, but in vitro culturing of cells from
these mice did reveal defects in myeloid maturation (23,
29). Thus, in vitro culture conditions seem to be more per-
missive for the manifestation of this defect. Importantly, a
recent study in which human CD34  enriched cells were
transduced with a retroviral vector expressing AML1-ETO
also noted a pronounced bias toward immature myeloid
cells after in vitro culture (65).
What is the molecular basis of the maturation block in
both the lymphoid and myeloid lineages and disruption of
normal erythropoiesis? Although several myeloid genes are
regulated by CBF (6, 7), accumulating evidence suggest
that AML1-ETO may exert its effect by protein interac-
tion with other transcription factors, such as PU.1 and
C/EBP  (18, 19, 64), both of which play a pivotal role in
myeloid differentiation, as demonstrated in knock-out
mice (66–68). This idea is supported by the recently ob-
served downregulation of the gene encoding C/EBP  (an
autoregulatory gene) in 30% of AML patients with a t(8;
21) karotype (21). With regard to the lymphoid compart-
ment, previous studies have shown that components of the
antigen receptor in both B and T cells are regulated by
CBF (5, 69). Thus, the downregulation of one or more of
these genes by AML1-ETO transcriptional repression may
interfere with lymphoid maturation by reducing receptor
levels. Alternatively, genes encoding proteins that act
downstream of antigen stimulation, e.g. the gene encoding
the B cell lymphocytic kinase blk that is also regulated by
CBF (70), may be important targets. Recent findings have
also shown that AML1 can interact with the B cell tran-
scription factor Pax5 (70). Potential target genes of
AML1-ETO transformation in erythroid cells have re-
cently been identified (71, 72). Our mouse model pro-
vides a reproducible system to further define the target
genes of AML-ETO transformation.1237 Schwieger et al.
Despite the profound effects on differentiation and mat-
uration observed in BM cells expressing AML1-ETO cells,
the mice remained aleukemic, underlining the importance
of secondary mutations in leukemia induction. The recent
finding that the gene encoding the tumor suppressor
ICSBP is downregulated in the hematopoietic compart-
ment in a large percentage of AML patients (41) prompted
us to determine if the differentiation impairment of AML1-
ETO–transduced myeloid cells would collaborate with
ICSBP deficiency to induce leukemia. AML1-ETO ex-
pression in the ICSBP /  background resulted in the accu-
mulation of morphologically altered myeloblasts (20–30%)
in the BM and the generation of granulocytic sarcoma-like
tumors, both pathognomonic features of t(8;21) AML (1,
54, 55). Thus, the ICSBP defect collaborates with AML1-
ETO to expand and transform a myeloblast population in
vivo. To our knowledge, this is the first identification of a
tumor suppressor that cooperates with AML1-ETO in my-
eloid transformation. Although the exact mechanism by
which ICSBP regulates growth control is not known,
genes regulating apoptosis (e.g., Bcl-x) (39) and growth
signaling (e.g., Dab2) (73) have been implicated as targets
of ICSBP regulation. It has recently been proposed that
ICSBP expression is downregulated by the CML oncogene
BCR-ABL, thus it will be of interest to determine if
ICSBP expression is a downstream target of other tyrosine
kinases, e.g., Flt3 and c-kit, which have been found to be
mutated in patients with t(8;21) AML (74, 75).
In summary, our results clearly demonstrate that AML1-
ETO expression can disrupt the proliferation and matura-
tion controls of several hematopoietic lineages in vivo.
Furthermore, we have identified ICSBP deficiency as a
secondary mutation that cooperates with AML1-ETO to
induce localized neoplasias, characterized by the accumula-
tion of  20% myeloblasts in the BM and the generation of
granulocytic sarcoma-like tumors. Noteworthy, these my-
eloblastic transformants remain confined to the bone (ex-
cept for one important exception), demonstrating the need
for subsequent mutations to induce the expansion and dis-
semination of these cells into other organs, including the
blood. Currently, we are using retroviral insertional mu-
tagenesis in the ICSBP /  model to define collaboration
oncogenes of AML1-ETO–induced AML.
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